Related Experiment Video

Updated: May 22, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

[Tailor-made strategy in HCV treatment]

Tsunamasa Watanabe1, Yasuhito Tanaka

  • 1Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 10, 2012
PubMed

Insights

Host genetic variations significantly impact Hepatitis C virus (HCV) infection outcomes and treatment responses. Genome-wide association studies reveal polymorphisms crucial for personalized HCV therapies.

Area of Science:

  • Virology
  • Genetics
  • Hepatology

Context:

  • Hepatitis C virus (HCV) infection is a major global health concern, leading to severe liver disease and cancer.
  • Current treatments achieve limited success, with only about 50% of patients responding to pegylated interferon-alpha and ribavirin.
  • Spontaneous viral clearance occurs in a minority of acute infections, suggesting host factors are involved.

Purpose:

  • To review the current evidence linking host genetic variations to Hepatitis C clinical outcomes.
  • To explore the role of genome-wide association studies (GWAS) in identifying these genetic factors.
  • To discuss the implications for developing personalized therapies for chronic Hepatitis C.

Summary:

  • Host genome variations play a critical role in Hepatitis C virus (HCV) infection progression and treatment efficacy.
  • Genome-wide association studies (GWAS) have identified specific genetic polymorphisms associated with HCV infection outcomes and adverse effects.
  • Understanding these host-pathogen interactions is key to improving treatment strategies.

Impact:

  • Identifies host genetic factors influencing Hepatitis C outcomes, aiding in risk stratification.
  • Highlights the potential for genotype-specific and personalized treatment approaches for chronic Hepatitis C.
  • Advances the understanding of host-virus interactions in viral hepatitis, paving the way for novel therapeutic targets.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...